Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents

These Guidelines were developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. Leadership of the Panel consists of Anthony S. Fauci, National Institutes of Health, Bethesda, MD (co-chair); John G. Bartlett, Johns Hopkins University, Baltimore, MD (co-chair); Eric P. Goosby, DHHS, Washington, DC, (co-convener); and Jennifer Kates, Henry J. Kaiser Foundation, San Francisco, CA, (co-convener).

Current members of the Panel include: Jean Anderson (Johns Hopkins University, Baltimore, MD), Rodney Armstead (UHP Healthcare, Inc., Inglewood, CA), A. Cornelius Baker (Whitman-Walker Clinic, Washington, DC), David Barr (Forum for Collaborative HIV Research, Washington, DC), Samuel A. Bozzette (SDVA Medical Center, San Diego, CA), Charles Carpenter (Brown University School of Medicine, Providence, RI), Martin Delaney (Project Inform, San Francisco, CA), Lawrence Deyton, (Dept. of Veterans Affairs, Washington, DC), Wafaa El- Sadr (Harlem Hospital, New York, NY), Fred Gordin, (Veterans Administration Medical Center, Washington, DC), Mark Harrington (Treatment Action Group, New York, NY), Martin S. Hirsch (Massachusetts General Hospital, Boston, MA), John W. Mellors (University of Pittsburgh, Pittsburgh, PA), James Neaton (University of Minnesota, Minneapolis, MN), Sallie Perryman (New York State Department of Health, New York, NY), John Phair (Northwestern University, Chicago, IL), Robert T. Schooley (University of Colorado, Denver, CO), Renslow Sherer (The CORE Center, Cook County Hospital, Chicago, IL), Stephen A. Spector (University of California San Diego, La Jolla, CA), Sharilyn K. Stanley (Texas Department of Health, Austin, TX), Paul Volberding (University of California, San Francisco, CA), Suzanne Willard (MCP Hahnemann University, Philadelphia, PA); participants from the Department of Health and Human Services: Victoria Cargill (National Institutes of Health), Oren Cohen (National Institutes of Health), T. Randolph Graydon (Health Care Financing Administration), Heidi Jolson (Food and Drug Administration), Jonathan Kaplan (Centers for Disease Control and Prevention), Abe Macher (Health Resources and Services Administration), Henry Masur (National Institutes of Health), Lynne Mofenson (National Institutes of Health), Jeffrey Murray (Food and Drug Administration), Joseph O'Neill (Health Resources and Services Administration), Alice Pau (National Institutes of Health), Lucille C. Perez (Substance Abuse and Mental Health Services Administration), Steve Piscitelli (National Institutes of Health). Nonvoting observers include: Gerry Bally (Health Canada, Ottawa, Ontario), Sophia Chang (Center for Quality HIV Care, V.A., Palo Alto, CA), Jeffrey Jacobs (AIDS Action Council, Washington, DC), Richard Marlink (Harvard AIDS Institute, Cambridge, MA), Celia Maxwell (AIDS Education and Training Center, Washington, DC), Howard Minkoff (Maimonides Medical Center, Brooklyn, NY), James Oleske (UMDNJ, Newark, NJ), Daniel Simpson (Indian Health Service, Rockville, MD)

Information included in these guidelines may not represent FDA approval or approved labeling for the particular products or indications in question. Specifically, the terms “safe” and “effective” may not be synonymous with the FDA-defined legal standards for product approval.